Global Cancer In Vitro Diagnostics (IVD) Market Insights 2029: Drivers, Challenges, and Revenue Forecast
Uncover key drivers, emerging technologies, and competitive movements shaping the cancer in vitro diagnostics (ivd) market from 2025–2034 with trusted insights from The Business Research Company
What Is The Current Size And Growth Outlook For The Cancer In Vitro Diagnostics (IVD) Market?
The cancer in vitro diagnostics (IVD) market size has demonstrated significant growth in recent years. Its valuation is projected to increase from $13.36 billion in 2024 to $14.32 billion in 2025, achieving a compound annual growth rate (CAGR) of 7.2%. This historical expansion is largely due to factors including boosted cancer biomarker research, a surge in oncological trials requiring testing, more government health initiatives, improved lab infrastructure support, and an uplift in biotech funding.
The cancer in vitro diagnostics (IVD) market is anticipated to experience robust expansion over the coming years, with its size projected to reach $18.62 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 6.8%. This growth throughout the forecast period is attributable to various factors, including screening initiatives by governments and NGOs, an expanding aging population, increasing awareness regarding early cancer diagnosis, broader reimbursement coverage, and the rising adoption of point-of-care (POC) diagnostics. Concurrently, major trends expected during this period involve the widespread development of liquid biopsy technologies, significant advancements in next-generation sequencing, the integration of artificial intelligence and machine learning, the incorporation of microfluidics, and the adoption of digital pathology.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27234&type=smp
What Growth-Enabling Forces Are Impacting The Cancer In Vitro Diagnostics (IVD) Market?
The rising occurrence of cancer is anticipated to propel the expansion of the cancer in vitro diagnostics (IVD) market in the future. Cancer is defined as the uncontrolled growth and spread of abnormal cells within the body, which can infiltrate nearby tissues and form tumors. This surge in cancer cases is primarily attributed to the aging demographic, where longer life expectancy and reduced mortality from infectious diseases result in a greater number of elderly individuals who face a higher risk of developing cancer. Cancer in vitro diagnostics (IVD) plays a crucial role in addressing cancer by enabling early and precise detection, monitoring, and management of the disease through laboratory tests performed on patient samples. This allows for timely treatment decisions and ultimately improves patient outcomes. For instance, in February 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, stated that the global number of new cancer cases reached 20 million in 2022 and is projected to increase to 35 million by 2050, signifying a 77% rise. Therefore, the escalating incidence of cancer is a key driver for the growth of the cancer in vitro diagnostics (IVD) market.
How Does The Cancer In Vitro Diagnostics (IVD) Market Differ By Segment?
The cancer in vitro diagnostics (IVD) market covered in this report is segmented
1) By Product Type: Reagents And Kits, Instruments, Software And Services
2) By Technology: Clinical Chemistry, Immunochemistry Or Immunoassays, Hematology, Coagulation And Hemostasis, Microbiology, Molecular Diagnostics, Other Technology
3) By Cancer Type: Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer
4) By End-Users: Hospitals, Laboratories, Academics, Point-Of-Care Testing, Patient Self-Testing, Other End Users
Subsegments:
1) By Reagents And Kits: PCR Reagents And Kits, NGS Reagents And Kits, Immunoassay Reagents And Kits, In Situ Hybridization (ISH) Reagents And Kits, Others
2) By Instruments: PCR Instruments, NGS Instruments, Immunoassay Analyzers, ISH Instruments, Others
3) By Software And Services: Data Analysis Software, Laboratory Information Management Systems, Cloud-Based Data Management, Instrument Integration Software, Support And Maintenance Services
What New Opportunities Are Emerging From Trends In The Cancer In Vitro Diagnostics (IVD) Market?
Companies active in the cancer in vitro diagnostics (IVD) market are concentrating on technological advancements, such as CE in vitro diagnostic (IVD) cancer testing kits, to boost the accessibility, accuracy, and standardization of hereditary cancer testing across various clinical settings. CE-in vitro diagnostic (IVD) cancer testing kits are diagnostic assays that conform to the European Union’s in vitro diagnostic directive (IVDD), assuring validated performance, safety, and quality for patient testing within European laboratories. For example, in February 2022, Invitae, a US-based medical genetics company, launched FusionPlex Dx and LiquidPlex Dx in Europe to enhance its oncology diagnostics portfolio. FusionPlex Dx provides sensitive detection of low-frequency variants in FFPE samples for routine clinical applications. LiquidPlex Dx enables non-invasive cancer genomic profiling from blood, offering rapid results and capturing tumor heterogeneity, making it valuable for personalized treatment and disease monitoring when tissue samples are scarce.
Who Are The Most Influential Companies In The Cancer In Vitro Diagnostics (IVD) Market?
Major companies operating in the cancer in vitro diagnostics (IVD) market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, GE HealthCare Technologies Inc., Hologic Inc., Illumina Inc., bioMérieux SA, Sysmex Corporation, Exact Sciences Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Autobio Diagnostics Co Ltd., Transasia Bio-Medicals Ltd., NanoString Technologies Inc., Genetron Holdings Limited, Cancer Diagnostics Inc., J. Mitra & Co. Pvt Ltd., and Tulip Diagnostics (P) Ltd.
Access The Complete Report Here:
Which Region Is Leading Innovation In The Cancer In Vitro Diagnostics (IVD) Market?
North America was the largest region in the cancer in vitro diagnostics (IVD) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer in vitro diagnostics (IVD) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=27234&type=smp
Browse Through More Reports Similar to the Global Cancer In Vitro Diagnostics (IVD) Market 2025, By The Business Research Company
Hvac And Commercial And Industrial Refrigeration Equipment Global Market Report 2025
Commercial Fan And Air Purification Equipment Global Market Report 2025
Farm Equipment Rental Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/farm-equipment-rental-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
